

# Lungenkarzinom

**NSCLC**  
(nicht-kleinzellig)

**SCLC**  
(kleinzellig)

**Resektion  
Stadium Ib-IIIa**

**Erste Linie  
Stadium IV**

**Fortgeschritten/Metastasiert  
Stadium IIIB/IV**

**Zweite Linie**

**Nach  
Adjuvante  
Therapie**

**ADAURA  
Phase III**

AZD9291 vs Placebo

EGFR Mutation Positive  
Stage IB-IIIa Non-small Cell  
Lung Carcinoma, following  
Complete Tumor  
Resection +/- Adjuvant  
Chemotherapy

**CANOPY  
(CACZ885T2301)  
Phase III**

CANAKINUMAB vs  
placebo

as adjuvant therapy in  
patients with stages  
AJCC/UICC v. 8 II -IIIA and  
IIIB (T>5cm N2)  
completely resected (R0)  
NSCLC

**MK-7902 / E7080-G000-315  
Phase III  
(geplant)**

Pemetrexed + Platinum  
Chemotherapy + Pembrolizumab  
(MK-3475) with or without  
Lenvatinib

in Participants with Treatment-  
naïve, Metastatic Non-squamous  
Non-small Cell Lung Cancer (NSCLC)

**BIOLUMA  
Phase II**

nivolumab + ipilimumab

evaluating biomarkers  
predictive for response to  
immune checkpoint inhibition  
in patients with non-  
squamous NSCLC

**BioMaSOTA**

Biologische Material  
Sammlung zur  
Optimierung  
Therapeutischer  
Ansätze, ein Projekt der  
CIO-Biobank Köln.

Ansprechpartner:

Dr. Julie George  
0221-478-98772  
0152-56498025  
[jgeorge@uni-koeln.de](mailto:jgeorge@uni-koeln.de)

**Dr. med. Jens Panse**  
[jpanse@ukaachen.de](mailto:jpanse@ukaachen.de)  
Tel: 0241-8089805

**Dr. med. Martin Kirschner**  
[mkirschner@ukaachen.de](mailto:mkirschner@ukaachen.de)  
Tel: 0241-8037130